Literature DB >> 6895157

Mullerian inhibiting substance inhibits growth of a human ovarian cancer in nude mice.

P K Donahoe, A F Fuller, R E Scully, S R Guy, G P Budzik.   

Abstract

Mullerian inhibiting substance (MIS) was investigated for its ability to inhibit growth of a human ovarian cancer in nude mice. Biologically active preparations from newborn calf testes, obtained after sequential ion exchange chromatography, delayed or prevented growth of a human ovarian cancer (HOC-21) when 2 X 10(6) cells were preincubated with them prior to subcutaneous injection of the tumor cells into Balb/C homozygous nude mice. Preincubation of a human colon carcinoma cells (SW-48) with similar preparations of MIS failed to inhibit growth of the tumor cells in nude mice. Human serous carcinomas are thought to arise from the ovarian surface epithelium, a derivative of the coelomic epithelium of the urogenital ridge, which invaginates to form the mullerian duct early in embryonic life. The neoplastic cells of serous tumors simulate morphologically the lining cells of the fallopian tube, which are derivatives of mullerian duct epithelium. This study provides physiologic confirmation of the mullerian nature of this type of tumor and suggests that MIS may ultimately prove to be effective in its therapy.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6895157      PMCID: PMC1345325          DOI: 10.1097/00000658-198110000-00010

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  21 in total

1.  Programmed cell death in the Müllerian duct induced by Müllerian inhibiting substance.

Authors:  J M Price; P K Donahoe; Y Ito; W H Hendren
Journal:  Am J Anat       Date:  1977-07

2.  A graded organ culture assay for the detection of Mullerian inhibiting substance.

Authors:  P K Donahoe; Y Ito; W H Hendren
Journal:  J Surg Res       Date:  1977-08       Impact factor: 2.192

3.  Hepatitis and brain lesions due to mouse hepatitis virus accompanied by wasting in nude mice.

Authors:  A Sebesteny; A C Hill
Journal:  Lab Anim       Date:  1974-09       Impact factor: 2.471

4.  Heterotransplantation of human adenocarcinomas of the colon and rectum to the mouse mutant Nude. A study of nine consecutive transplantations.

Authors:  C O Povlsen; J Rygaard
Journal:  Acta Pathol Microbiol Scand A       Date:  1971

5.  The cellular biology of a newly established cell line of human ovarian adenocarcinoma in vitro.

Authors:  T Yamada
Journal:  Keio J Med       Date:  1974-06

6.  Heterotransplantation of human epidermoid carcinomas to the mouse mutant nude.

Authors:  C O Povlsen; J Rygaard
Journal:  Acta Pathol Microbiol Scand A       Date:  1972

7.  Heterotransplantation of a human malignant tumour to "Nude" mice.

Authors:  J Rygaard; C O Povlsen
Journal:  Acta Pathol Microbiol Scand       Date:  1969

8.  [Action of the fetal testis on the development in vitro of the Müllerian ducts in the rat].

Authors:  R Picon
Journal:  Arch Anat Microsc Morphol Exp       Date:  1969 Jan-Mar

9.  Classification of human colorectal adenocarcinoma cell lines.

Authors:  A Leibovitz; J C Stinson; W B McCombs; C E McCoy; K C Mazur; N D Mabry
Journal:  Cancer Res       Date:  1976-12       Impact factor: 12.701

10.  The pathogenesis of ovarian inclusion cysts and cystomas.

Authors:  S V Radisavljevic
Journal:  Obstet Gynecol       Date:  1977-04       Impact factor: 7.661

View more
  9 in total

1.  Tissue-engineered cells producing complex recombinant proteins inhibit ovarian cancer in vivo.

Authors:  A E Stephen; P T Masiakos; D L Segev; J P Vacanti; P K Donahoe; D T MacLaughlin
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

2.  Transformation-specific cell killing by a cancer-associated galactosyltransferase acceptor and cellular binding.

Authors:  D K Podolsky; K J Isselbacher
Journal:  Biochem J       Date:  1982-11-15       Impact factor: 3.857

3.  Anti-Müllerian hormone and risk of ovarian cancer in nine cohorts.

Authors:  Seungyoun Jung; Naomi Allen; Alan A Arslan; Laura Baglietto; Aurelio Barricarte; Louise A Brinton; Brian L Egleston; Roni T Falk; Renée T Fortner; Kathy J Helzlsouer; Yutang Gao; Annika Idahl; Rudolph Kaaks; Vittorio Krogh; Melissa A Merritt; Eva Lundin; N Charlotte Onland-Moret; Sabina Rinaldi; Helena Schock; Xiao-Ou Shu; Patrick M Sluss; Paul N Staats; Carlotta Sacerdote; Ruth C Travis; Anne Tjønneland; Antonia Trichopoulou; Shelley S Tworoger; Kala Visvanathan; Elisabete Weiderpass; Anne Zeleniuch-Jacquotte; Joanne F Dorgan
Journal:  Int J Cancer       Date:  2017-10-04       Impact factor: 7.396

Review 4.  Müllerian inhibiting substance/anti-Müllerian hormone: a potential therapeutic agent for human ovarian and other cancers.

Authors:  David T MacLaughlin; Patricia K Donahoe
Journal:  Future Oncol       Date:  2010-03       Impact factor: 3.404

5.  Mullerian Inhibiting Substance inhibits cervical cancer cell growth via a pathway involving p130 and p107.

Authors:  Thanh U Barbie; David A Barbie; David T MacLaughlin; Shyamala Maheswaran; Patricia K Donahoe
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-11       Impact factor: 11.205

Review 6.  Müllerian inhibiting substance/anti-Müllerian hormone: A novel treatment for gynecologic tumors.

Authors:  Jang Heub Kim; David T MacLaughlin; Patricia K Donahoe
Journal:  Obstet Gynecol Sci       Date:  2014-09-17

7.  Anti-Mullerian hormone and endometrial cancer: a multi-cohort study.

Authors:  Renée T Fortner; Helena Schock; Seungyoun Jung; Naomi E Allen; Alan A Arslan; Louise A Brinton; Brian L Egleston; Roni T Falk; Marc J Gunter; Kathy J Helzlsouer; Annika Idahl; Theron S Johnson; Rudolf Kaaks; Vittorio Krogh; Eva Lundin; Melissa A Merritt; Carmen Navarro; N Charlotte Onland-Moret; Domenico Palli; Xiao-Ou Shu; Patrick M Sluss; Paul N Staats; Antonia Trichopoulou; Elisabete Weiderpass; Anne Zeleniuch-Jacquotte; Wei Zheng; Joanne F Dorgan
Journal:  Br J Cancer       Date:  2017-09-05       Impact factor: 7.640

Review 8.  Translational Physiology of Anti-Müllerian Hormone: Clinical Applications in Female Fertility Preservation and Cancer Treatment.

Authors:  Rachael Jean Rodgers; Jason Anthony Abbott; Kirsty A Walters; William Leigh Ledger
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-07       Impact factor: 5.555

9.  A comparison of the growth promoting properties of ascitic fluids, cyst fluids and peritoneal fluids from patients with ovarian tumours.

Authors:  A P Wilson; H Fox; I V Scott; H Lee; M Dent; P R Golding
Journal:  Br J Cancer       Date:  1991-01       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.